Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Advanced Ovarian Cancer
NCT03547375Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Jun 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in ovarian cancer, sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Progression-Free Survival at 12 weeks. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03547375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03547375.